中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
21期
1389-1393
,共5页
程皖琴%郑斯明%苏勇%吴峥%周树%胡江
程皖琴%鄭斯明%囌勇%吳崢%週樹%鬍江
정환금%정사명%소용%오쟁%주수%호강
鼻咽癌%调强放射治疗%涎腺%口腔%口干燥症
鼻嚥癌%調彊放射治療%涎腺%口腔%口榦燥癥
비인암%조강방사치료%연선%구강%구간조증
nasopharyngeal carcinoma%intensity modulated radiotherapy%salivary gland%oral cavity%xerostomia
目的:探讨鼻咽癌适形调强放疗(intensity modulate radiation therapy,IMRT)患者各涎腺功能的保护方法。方法:选取2010年3月至2012年11月101例连续于中山大学肿瘤医院接受IMRT鼻咽癌患者,勾画危及器官,包括腮腺、颌下腺、口腔,于3、6、12、18、24个月复查时采用面对面访谈式问卷调查评分口干程度情况,并结合剂量体积直方图(dose-volume histograms,DVH)进行分析。结果:腮腺平均剂量(MD)为37.4 Gy(患侧),33.8 Gy(健侧);颌下腺MD为51.6 Gy(患侧),45.7 Gy(健侧);口腔MD为38.2 Gy。77.2%(78/101)患者放疗结束后6个月口干症状明显改善,1年后中度(G3)以上口干患者<5.0%(5/101)。结论:随着时间的推移,放疗后口干燥症明显改善;限定至少一侧腮腺V30~35≤50.0%,至少一侧颌下腺V40~45≤66.7%~50.0%,口腔MD<40 Gy可有效保护唾液腺功能。
目的:探討鼻嚥癌適形調彊放療(intensity modulate radiation therapy,IMRT)患者各涎腺功能的保護方法。方法:選取2010年3月至2012年11月101例連續于中山大學腫瘤醫院接受IMRT鼻嚥癌患者,勾畫危及器官,包括腮腺、頜下腺、口腔,于3、6、12、18、24箇月複查時採用麵對麵訪談式問捲調查評分口榦程度情況,併結閤劑量體積直方圖(dose-volume histograms,DVH)進行分析。結果:腮腺平均劑量(MD)為37.4 Gy(患側),33.8 Gy(健側);頜下腺MD為51.6 Gy(患側),45.7 Gy(健側);口腔MD為38.2 Gy。77.2%(78/101)患者放療結束後6箇月口榦癥狀明顯改善,1年後中度(G3)以上口榦患者<5.0%(5/101)。結論:隨著時間的推移,放療後口榦燥癥明顯改善;限定至少一側腮腺V30~35≤50.0%,至少一側頜下腺V40~45≤66.7%~50.0%,口腔MD<40 Gy可有效保護唾液腺功能。
목적:탐토비인암괄형조강방료(intensity modulate radiation therapy,IMRT)환자각연선공능적보호방법。방법:선취2010년3월지2012년11월101례련속우중산대학종류의원접수IMRT비인암환자,구화위급기관,포괄시선、합하선、구강,우3、6、12、18、24개월복사시채용면대면방담식문권조사평분구간정도정황,병결합제량체적직방도(dose-volume histograms,DVH)진행분석。결과:시선평균제량(MD)위37.4 Gy(환측),33.8 Gy(건측);합하선MD위51.6 Gy(환측),45.7 Gy(건측);구강MD위38.2 Gy。77.2%(78/101)환자방료결속후6개월구간증상명현개선,1년후중도(G3)이상구간환자<5.0%(5/101)。결론:수착시간적추이,방료후구간조증명현개선;한정지소일측시선V30~35≤50.0%,지소일측합하선V40~45≤66.7%~50.0%,구강MD<40 Gy가유효보호타액선공능。
Objective:To investigate the protective effect of intensity-modulated radiotherapy (IMRT) on salivary gland function in nasopharyngeal carcinoma (NPC) patients. Methods:In total, 101 NPC patients who were admitted from March 2010 to November 2012 were enrolled in this study. The parotid gland, the submandibular gland, and the oral cavity were sketched as the organs at risk (OARs). The patients were treated with IMRT and were evaluated through a face-to-face interview using a dry mouth assessment ques-tionnaire during the follow-up visits at 3, 6, 12, 18, and 24 months. The dose volume histogram of the salivary gland of the patients was also considered. Results:The mean doses (MDs) in the parotid gland were 37.4 and 33.8 Gy in the affected and uninjured sides, respec-tively. Meanwhile, the MDs in the submandibular glands were 51.6 and 45.7 Gy in the affected and uninjured sides, respectively. The MD of the oral cavity was 38.2 Gy. At 6 months after the treatment, the symptom of xerostomia was significantly improved in 77.2%of the patients (78/101). One year later, only less than 5%of the patients complained of having G3 or higher-grade xerostomia. Conclu-sion:With time, xerostomia significantly improved after the radiotherapy. At least one of the V30 to V35 of the parotid gland was≤50.0%, whereas at least one of the V40 to V45 of the submandibular glands was≤66.7%~50.0%. The MD for the oral cavity should be<40 Gy to effectively protect salivary gland function.